Harvest Investment Advisors LLC Invests $1.81 Million in Gilead Sciences, Inc. $GILD

Harvest Investment Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, HoldingsChannel.com reports. The fund bought 14,702 shares of the biopharmaceutical company’s stock, valued at approximately $1,805,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $61,000. Arthur M. Cohen & Associates LLC boosted its stake in Gilead Sciences by 20.7% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 3,030 shares of the biopharmaceutical company’s stock valued at $372,000 after purchasing an additional 520 shares during the period. Captrust Financial Advisors boosted its stake in Gilead Sciences by 1.5% in the 4th quarter. Captrust Financial Advisors now owns 1,936,138 shares of the biopharmaceutical company’s stock valued at $237,642,000 after purchasing an additional 28,012 shares during the period. &PARTNERS boosted its stake in Gilead Sciences by 16.3% in the 4th quarter. &PARTNERS now owns 352,784 shares of the biopharmaceutical company’s stock valued at $43,309,000 after purchasing an additional 49,405 shares during the period. Finally, Siemens Fonds Invest GmbH boosted its stake in Gilead Sciences by 15.8% in the 4th quarter. Siemens Fonds Invest GmbH now owns 59,922 shares of the biopharmaceutical company’s stock valued at $7,381,000 after purchasing an additional 8,177 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 68,000 shares of company stock valued at $8,930,150. Insiders own 0.30% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention, advancing a potential new long-acting PrEP option and opening a possible new growth driver for the company. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, signaling continued analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Two Gilead insiders, including CFO Andrew D. Dickinson and Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. The sales were disclosed normally and do not appear to signal an abrupt change in outlook, but they can still weigh on sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
• Neutral Sentiment: Recent reports noted GILD had previously dipped modestly in the prior session, but the stock’s latest move appears tied more to the FDA milestone and analyst support than to broader market action. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences Trading Up 2.4%

Shares of Gilead Sciences stock opened at $127.23 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The stock has a 50 day moving average price of $132.61 and a two-hundred day moving average price of $134.32. The stock has a market capitalization of $157.96 billion, a PE ratio of 17.33 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is 44.69%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on GILD shares. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Daiwa Securities Group cut their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. The Goldman Sachs Group upped their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Finally, Jefferies Financial Group started coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price for the company. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $158.41.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.